Table 2.
Characteristic | No (%) of patients |
P value | |
---|---|---|---|
MDR P. mirabilis group (n = 36) | Non-MDR P. mirabilis group (n = 63) | ||
Demographics | |||
Male sex | 25 (69.4) | 37 (58.7) | 0.28 |
Age >65 years | 14 (38.8) | 40 (63.5) | 0.01 |
Comorbidities | |||
Solid tumor | 14 (38.9) | 17 (26.9) | 0.21 |
Hematological malignancy | 4 (11.1) | 6 (9.5) | 0.80 |
Liver disease | 6 (16.7) | 8 (12.7) | 0.58 |
Chronic renal failure | 15 (41.7) | 10 (15.9) | 0.004 |
Diabetes | 10 (27.8) | 14 (22.2) | 0.53 |
Charlson index ≥3 | 17 (47.2) | 32 (50.8) | 0.73 |
Immunosuppressive therapy | 8 (22.2) | 22 (34.9) | 0.18 |
Epidemiological category | |||
HCA BSI detected ≥48 h postadmission | 29 (80.5) | 53 (84.1) | 0.65 |
HCA BSI detected <48 h postadmission | 5 (13.9) | 6 (9.5) | 0.50 |
Community-acquired BSI | 2 (5.5) | 4 (6.3) | 0.87 |
Clinical presentation | |||
Source of infection | |||
Central venous catheter | 0 | 4 (6.3) | 0.12 |
Abdominal cavity | 3 (8.3) | 2 (3.2) | 0.26 |
Lower respiratory tract | 1 (2.8) | 2 (3.2) | 0.91 |
Surgical wound | 4 (11.1) | 1 (1.6) | 0.03 |
Urinary tract | 19 (52.8) | 28 (44.4) | 0.42 |
Unknown | 12 (33.3) | 28 (44.4) | 0.27 |
Shock | 8 (22.2) | 22 (34.9) | 0.18 |
APACHE III score (median [range])a | 38 (10–71) | 45 (3–118) | 0.07 |
Inadequate initial antimicrobial therapy | 14 (38.8) | 7 (11.1) | 0.001 |
Outcomes | |||
Treatment failure after the first 72 h | 20 (55.5) | 23 (36.5) | 0.06 |
21-day mortality | 18 (50) | 12 (19.1) | 0.001 |
Median (range) post-BSI hospital stay (days) for patients discharged alive | 34 (8–129) | 14 (2–105) | 0.001 |
Calculated on the basis of chart data relative to the 24 h following BSI onset. When data were missing for one variable, that variable was assigned a value of 0 indicating that it was within normal limits. If more than one variable was missing, the case was excluded from the study.
Data are expressed as number (%) unless otherwise stated. Abbreviations: BSI, bloodstream infection; HCA, health care associated (as defined in Materials and Methods); MDR, multidrug resistant.